Key non-oncology meds came up big for AstraZeneca in Q3—but that's not what analysts wanted to talk about on the earnings conference call.
Drugmaker Lundbeck saw its shares fall more than 8.35% after sales of the Danish drugmaker's newer meds failed to live up to analyst expectations.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
Last week, Teva's CFO said executives would be “evaluating all options” for easing the company’s debt burden. But that list of options is shrinking.
Valeant's third-quarter results provided a welcome dose of good news as the company works to execute its lengthy turnaround.
Floundering Teva is struggling under debt pressure—but it may have a billionaire who can help with that.
For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan's third-quarter results.
When Allergan CEO Brent Saunders said Wednesday that cost cuts were coming, he didn’t say where. But commercial chief Bill Meury did.
Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.
On a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same.
Questioned on Amazon's potential entry into drug sales, pharma executives are encouraging changes in the drug distribution system.